APEX1 and pancreatic neoplasm: Apexian pharmaceuticals is taking a different approach in developing a drug that binds to APE1/Ref-1, a dual protein that is crucial in the development and growth of tumors in pancreatic cancer and is particularly dependent on APE1/Ref-1 [33].